These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 25504896)
1. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P Rheumatology (Oxford); 2015 Jul; 54(7):1170-6. PubMed ID: 25504896 [TBL] [Abstract][Full Text] [Related]
2. Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry. Thiele F; Klein A; Windschall D; Hospach A; Foeldvari I; Minden K; Weller-Heinemann F; Horneff G Rheumatol Int; 2021 Apr; 41(4):751-762. PubMed ID: 33590331 [TBL] [Abstract][Full Text] [Related]
3. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease? Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614 [TBL] [Abstract][Full Text] [Related]
4. Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting. Pastore S; Naviglio S; Canuto A; Lepore L; Martelossi S; Ventura A; Taddio A Paediatr Drugs; 2018 Apr; 20(2):165-171. PubMed ID: 29214394 [TBL] [Abstract][Full Text] [Related]
5. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Gerloni V; Pontikaki I; Gattinara M; Fantini F Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916 [TBL] [Abstract][Full Text] [Related]
6. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155 [TBL] [Abstract][Full Text] [Related]
11. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Bonafede M; Fox KM; Watson C; Princic N; Gandra SR Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712 [TBL] [Abstract][Full Text] [Related]
12. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061 [TBL] [Abstract][Full Text] [Related]
13. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry. Foeldvari I; Becker I; Horneff G Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824 [TBL] [Abstract][Full Text] [Related]
14. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up. Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496 [TBL] [Abstract][Full Text] [Related]
16. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Otten MH; Prince FH; Anink J; Ten Cate R; Hoppenreijs EP; Armbrust W; Koopman-Keemink Y; van Pelt PA; Kamphuis S; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374 [TBL] [Abstract][Full Text] [Related]
18. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Calvo-Río V; Santos-Gómez M; Calvo I; González-Fernández MI; López-Montesinos B; Mesquida M; Adán A; Hernández MV; Maíz O; Atanes A; Bravo B; Modesto C; Díaz-Cordovés G; Palmou-Fontana N; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R Arthritis Rheumatol; 2017 Mar; 69(3):668-675. PubMed ID: 27696756 [TBL] [Abstract][Full Text] [Related]
19. Retention on anti-tumour necrosis factor therapy: the Waikato experience. Ip K; Hartley L; Solanki K; White D N Z Med J; 2015 May; 128(1415):34-40. PubMed ID: 26117510 [TBL] [Abstract][Full Text] [Related]
20. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]